clinical trial · NCT04586010
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Hoffmann-La Roche·phase3·active not recruiting·n = 746
Relapsing Multiple SclerosisFenebrutinibTeriflunomidePlacebo
brief summary
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. At the end of the DBT phase (after disclosure of the DBT results), the Sponsor will determine whether or not to initiate the open-label extension phase of the study.
started
Mar 17, 2021
primary completion
Jan 27, 2026
completion
Nov 30, 2027
last updated
Feb 17, 2026
official title
A Phase III Multicenter Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Adult Patients With Relapsing Multiple Sclerosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol